Industry Briefs: Apr. 16, 2012

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Apr 19, 2012
By PharmTech Editors

Company News

AMRI and Biota have agreed to develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. Read More

Evans Analytical Group (EAG) has acquired PTRL West and PTRL Europe. Read More

Nascent and Catalent Pharma Solutions have formed a product-development agreement for a Nascent antibody drug candidate. Read More

Pharmatek has added to its liquid encapsulation capabilities. Read More

Q Laboratories has completed construction on its 5000-ft2 microbiology research and development laboratory.

Shire has agreed to acquire Pervasis Therapeutics and related endothelial cell technology. Read More

Vanda Pharmaceuticals has acquired the rights to an NK-1 receptor antagonist from Eli Lilly. Read More

People News

Hospira has named John B. Elliot senior vice-president of operations. Read More

Penn Pharma has appointed Jerome Detreille as senior director of new business development. Read More

Michael A. Griffith has been appointed to Repligen’s board of directors. Read More